skip to main |
skip to sidebar
"On Thursday, specialty drug developer Neurochem (Nasdaq: NRMX) made two announcements. One was the timeline for the upcoming release of phase 3 clinical trial data for its Alzheimer's drug candidate, Alzhemed. The other was a change to how its statisticians review the data from the trial.
Neurochem completed the pivotal 1,052-person Alzhemed study in February. The upcoming clinical trial results from this study are expected to be announced sometime in the second quarter, and will determine whether the drug has any chance of achieving marketing approval without the need for more clinical trial work."
